ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,399Medicare Part D Prescriptions Filled, Including Refills

Rank: 47 out of 434

$544K Total Retail Price of All Prescriptions

Rank: 33 out of 434

614 Patients Receiving at Least One Drug in Part D
87%Patients 65 Years and Older
11% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nevada
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 614 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

14% of this provider’s 614 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 8,148 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$58 was the average price of a prescription from this provider, compared to $52 among peers.

Prescriptions per Patient

15 is the average number of prescriptions (including refills) per patient, compared to an average of 13.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nevada
SIMVASTATIN 545 499 1 2
LEVOTHYROXINE SODIUM 469 418 2 3
AMLODIPINE BESYLATE 367 339 3 6
LISINOPRIL 353 337 4 1
OMEPRAZOLE 347 291 5 5
HYDROCODONE-ACETAMINOPHEN 284 240 S3 6 4
PRAVASTATIN SODIUM 245 222 7 17
ALENDRONATE SODIUM 226 204 8 15
ZOLPIDEM TARTRATE 206 187 9 11
LOSARTAN POTASSIUM 205 192 10 13
GABAPENTIN 161 123 11 14
AZITHROMYCIN 157 135 12 38
METOPROLOL SUCCINATE 149 121 13 22
ATORVASTATIN CALCIUM 140 129 14 19
ATENOLOL 127 121 15 16
CITALOPRAM HBR 122 90 16 23
LOSARTAN-HYDROCHLOROTHIAZIDE 116 108 17 39
HYDROCHLOROTHIAZIDE 115 109 18 8
METFORMIN HCL ER 110 92 19 48
METFORMIN HCL 103 90 20 7
TRAMADOL HCL 96 92 21 28
CIPROFLOXACIN HCL 90 79 22 55
METHYLPREDNISOLONE 87 77 23 89
FUROSEMIDE 86 69 24 9
TRAZODONE HCL 85 58 25 33
FLUTICASONE PROPIONATE 81 70 26 26
METOPROLOL TARTRATE 74 68 27 12
LOVASTATIN 74 74 27 10
AMOX TR-POTASSIUM CLAVULANATE 72 64 29 113
LISINOPRIL-HYDROCHLOROTHIAZIDE 71 67 30 21
WARFARIN SODIUM 67 58 31 18
SYNTHROID 62 62 32 67
TAMSULOSIN HCL 60 59 33 29
PANTOPRAZOLE SODIUM 60 48 33 66
ESTRADIOL 58 36 R 35 73
NEXIUM 57 57 36 95
BENAZEPRIL HCL 57 55 36 49
SERTRALINE HCL 56 54 38 27
GLIPIZIDE 54 49 39 37
FENOFIBRATE 52 38 40 43
ALLOPURINOL 51 46 41 25
FLUOXETINE HCL 51 45 41 32
ADVAIR DISKUS 50 38 43 52
TRIAMTERENE-HCTZ 50 50 43 47
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 11, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.